NASDAQ : ESPR
Esperion Therapeutics, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 3.18 USD (At close: Jul 10, 2026) · Market cap 819.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 819.46M |
| Enterprise Value | 1.21B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 257.69M |
| Shares Outstanding | 257.69M |
| Shares Change (YoY) | +14.32% |
| Shares Change (QoQ) | -11.67% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 63.11% |
| Float | 234.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.96 |
| Forward PS | 2.26 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.89 |
| EV / EBITDA | 15.91 |
| EV / EBIT | 15.93 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.53 |
| Quick Ratio | 0.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | 6.94 |
| Debt / FCF | n/a |
| Interest Coverage | 0.89 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 12.04% |
| Return on Invested Capital (ROIC) | 23.47% |
| Return on Capital Employed (ROCE) | 46.73% |
| Weighted Average Cost of Capital (WACC) | 10.99% |
| Revenue Per Employee | $1.42M |
| Profits Per Employee | -$25,248 |
| Employee Count | 294 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 1.37 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.84M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +158.54% |
| 50-Day Moving Average | 3.10 |
| 200-Day Moving Average | 3.06 |
| Relative Strength Index (RSI) | 64.75 |
| Average Volume (20 Days) | 16,181,762 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17.40M |
| Short Previous Month | 20.72M |
| Short % of Shares Out | 6.75% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 1.58 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 418.24M |
| Gross Profit | 241.70M |
| Operating Income | 75.79M |
| Pretax Income | -5.58M |
| Net Income | -7.42M |
| EBITDA | 75.89M |
| EBIT | 75.79M |
| Loss Per Share | -$0.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 156.16M |
| Total Debt | 543.81M |
| Net Cash | -387.65M |
| Net Cash Per Share | -$1.50 |
| Equity (Book Value) | -307.93M |
| Book Value Per Share | -1.20 |
| Working Capital | 159.10M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -18.19M |
| Capital Expenditures | -189,000 |
| Depreciation & Amortization | 106,000 |
| Net Borrowing | -54.91M |
| Free Cash Flow | -18.38M |
| FCF Per Share | -$0.07 |
Margins
| Measure | Value |
|---|
| Gross Margin | 57.79% |
| Operating Margin | 18.12% |
| Pretax Margin | -1.33% |
| Profit Margin | -1.77% |
| EBITDA Margin | 18.15% |
| EBIT Margin | 18.12% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.32% |
| Shareholder Yield | -14.32% |
| Earnings Yield | -0.91% |
| FCF Yield | -2.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.19 |
| Price Target Difference | 0.31% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 12.04% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.72 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |